Hikma Pharmaceutical | HIK - Net Income


Hikma Pharmaceutical reported $164M in Net Income for its fiscal semester ending in December of 2025.





Net Income Change Date
Almirall EUR 19.58M 7M Dec/2025
argenx SE USD 366M 166.95M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Autolus Therapeutics Ltd USD -90.33M 11.21M Dec/2025
Bayer EUR 2.76B 6.52B Mar/2026
Fresenius EUR 361M 17M Dec/2025
Genmab DKK 31M 370M Dec/2025
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
GRIFOLS EUR 73M 25.25M Mar/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Lakefront Biotherapeutics EUR 14.49M 767.65M Mar/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 659M 340M Mar/2026
Orion EUR 90.4M 170.1M Mar/2026
Recordati EUR 153.06M 35.75M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
UCB EUR 1.08B 608M Dec/2025